Global Recurrent Glioblastoma Multiforme Treatment Market to Reach Up To US$ 560.9 Million by 2027, Says Coherent Market Insights (CMI) | Financial Buzz

Global Recurrent Glioblastoma Multiforme Treatment Market to Reach Up To US$ 560.9 Million by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global recurrent glioblastoma multiforme treatment market is estimated to be valued at US$ 369.6 million in 2020 and is projected to exhibit a CAGR of 6.14% during the forecast period (2020-2027).

Key Trends and Analysis:

The global recurrent glioblastoma multiforme treatment market is expected to witness noteworthy growth, owing to advancements in treatment and novel drug approvals. For instance, in January 2020, Pfizer launched a bevacizumab biosimilar drug, ‘Zirabev’, in the U.S. for the treatment of recurrent glioblastoma multiforme. Zirabev acts as a substitute for Avastin and is priced at a WAC (Wholesale Acquisition Cost) of US$ 61.34 per 10 mg. The U.S. FDA approved this biosimilar in June 2019 for the treatment of recurrent glioblastoma multiforme, metastatic or recurrent NSCLC, recurrent/persistent or metastatic cervical cancer, metastatic colorectal cancer, and metastatic renal cell carcinoma.

For instance, in November 2019, the U.S. FDA accepted Samsung’s BLA application for SB8 bevacizumab, a biosimilar of Avastin. If this will gets approval, thisen, the biosimilar will be commercialized in the U.S. market by Merck & Co., Inc., which has also been Samsung’s partner on its biosimilar of infliximab – RenflexisKey industry players are implementing research collaborations and joint ventures to discover & develop novel drugs, which is significantly driving growth of the market. For instance, in October 2019, UCLA and Advaxix jointly entered into an agreement for research on GBM immunotherapy products. The companies aimed to conduct preclinical studies evaluating the Lm technology of UCLA in mouse tumor models of glioblastoma multiforme.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/682

Key Market Takeaways:

The global recurrent glioblastoma multiforme treatment market is expected to exhibit a CAGR of 6.1% during the forecast period (2020-2027), owing to the collaborations by key players. For instance, in May 2017, DelMar Pharmaceuticals formalized the collaboration agreement with PRA Health Sciences, in order to conduct VAL-083’s phase III trials for the treatment of recurrent glioblastoma multiforme.

North America recurrent glioblastoma multiforme treatment market is expected to be the most lucrative region during the forecast period, owing to increasing investments in R&D activities and FDA approvals for clinical trials in this region. For instance, in October 2019, Denovo Biopharma was granted the FDA approval for its phase IIb clinical trial assessing an analytical permutation therapy for the treatment of newly diagnosed GBM patients.

Competitive Landscape:

Key players operating in the global recurrent glioblastoma multiforme treatment market include GlaxoSmithKline plc., GW Pharmaceuticals Plc, AstraZeneca, ImmunoCellular Therapeutics, Ltd., F. Hoffman-La Roche, Ltd., Genzyme Corporation, Pfizer, Inc., ERC Belgium SA, Merck & Co., Inc., GenSpera, Inc., Vascular Biogeneics, EnGeneIC Ltd., AngioChem, Inc., Boehringer Ingelheim GmbH, Cortice Biosciences, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Boston Biomedical, Inc., Eisai, Cantex Pharmaceuticals, Inc., Coherus BioSciences, Inc., Celldex Therapeutics, Inc., and Cavion LLC

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/682

Market Segmentation:

  • By Treatment:

    • Oral Medications
    • Radiosensitizers
    • Nitrosoureas Drugs
    • Chemotherapy
  • By Type:

    • Grade II or Grade III
    • Grade IV
    • Others
  • By Region:

    • North America

      • By Country:

        • U.S.
        • Canada
    • Europe

      • By Country:

        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific

      • By Country:

        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
    • Latin America

      • By Country:

        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East

      • By Country:

        • GCC
        • Israel
        • Rest of Middle East
    • Africa

      • By Region:

        • North Africa
        • Central Africa
        • South Africa

Related Market Intelligence Reports:

Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Read more: https://www.coherentmarketinsights.com/market-insight/urinary-incontinence-treatment-drugs-market-4400

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.

Contacts

Mr. Shah

Senior Client Partner – Business Development

Coherent Market Insights

Phone:

US:
+1-206-701-6702

UK: +44-020-8133-4027

Japan: +81-050-5539-1737

India: +91-848-285-0837

Email: sales@coherentmarketinsights.com

Website: https://www.coherentmarketinsights.com

Follow Us: LinkedIn | Twitter